Skip to search formSkip to main contentSkip to account menu

CGS 22652

Known as: CGS-22652 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

CaprylatesSulfonamides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1995
1995
Role of cyclooxygenase metabolites in mediating platelet-induced baroreceptor dysfunction.
The goal of the study was to determine the role of cyclooxygenase metabolites in mediating platelet-induced suppression of… 
1994
1994
A quantitative analytical method for the determination of a new thromboxane synthetase inhibitor (CGS 22652) in human plasma using high performance liquid chromatography.
A quantitative analytical method for the determination of a new thromboxane synthetase inhibitor (CGS 22652) in human plasma has… 
1993
1993
Beneficial effects of combined thromboxane synthase inhibition/receptor blockade with CGS 22652 in a canine model of coronary thrombosis.
1993
1993
BLOOD PRESSURE EFFECTS OF THROMBOXANE A2 BLOCKADE IN SPONTANEOUSLY HYPERTENSIVE RATS
1. The effects of CGS 22652, a thromboxane (Tx) A2 synthase inhibitor and TxA2 prostaglandin (PG) H2 receptor antagonist, on… 
1992
1992
CGS 22652: A New Potent Thromboxane A2 Receptor Antagonist with Selective Thromboxane A2 Synthase Inhibitory Properties
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)